For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Zafgen, Inc.

USPTO Granted Patents = 48

% Expired Patents = 97.9

CIPO Patents = 4

EPO Patents = 17

Trademarks = 1

Forward Citations = 283

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

James E Vath (26 out of 27 patents)

Robert Zahler (19 out of 74 patents)

Thomas David Pallin (14 out of 30 patents)

4. Susan Mary Cramp (14 out of 15 patents)

5. Hazel Joan Dyke (13 out of 32 patents)

6. Thomas Edward Hughes (13 out of 15 patents)

7. Thomas Crawford (5 out of 8 patents)

8. Hayley A Reece (4 out of 4 patents)

9. Alan Cherrington (2 out of 3 patents)

10. David Edward Clark (2 out of 26 patents)

11. Stuart Chaffee (2 out of 2 patents)

12. Janusz Jozef Kulagowski (1 out of 73 patents)

13. Zhenwei Cai (1 out of 20 patents)

14. Zhixing Wu (1 out of 1 patent)

15. John Gary Montana (1 out of 68 patents)

Core Competencies:

Obesity

Liver Diseases

Tricyclic Compounds

MetAP-2 Inhibitor

Fumigillol

Sulphonamide

Ischemic Organ Damage

Wound Healing

Renal Disease

Amino Peptidase Modulators

Tetrazole Compounds

Fused Bicyclic Compounds

48 patents: Sort by Forward Citations

1. 10406134 - Methods of treating an overweight subject (2019-09-10),

2. 10259796 - Oxaspiro[2.5]octane derivatives and analogs (2019-04-16),

3. 10231946 - Methods of treating ischemic organ damage and other disorders (2019-03-19),

4. 10220015 - Fumigillol compounds and methods of making and using same (2019-03-05),

5. 10174009 - Tricyclic sulphonamide compounds and methods of making and using same (2019-01-08),

6. 10064839 - Methods of treating liver diseases (2018-09-04),

7. 10023561 - Fumagillol heterocyclic compounds and methods of making and using same (2018-07-17),

8. 9944613 - Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same (2018-04-17),

9. 9925166 - Methods of treating an overweight or obese subject (2018-03-27),

10. 9895339 - Fumigillol compounds and methods of making and using same (2018-02-20),

11. 9868717 - Tricyclic sulphonamide compounds and methods of making and using same (2018-01-16),

12. 9849106 - Methods of treating impaired wound healing (2017-12-26),

13. 9839623 - Tricyclic compounds and methods of making and using same (2017-12-12),

14. 9839622 - Methods of treating hypothalamic obesity (2017-12-12),

15. 9827221 - Crystalline solids of a metAP-2 inhibitor and methods of making and using same (2017-11-28),

Company Overview

Zafgen, Inc. is a biotechnology company based in Boston, MA, focused on developing innovative therapies for obesity and related metabolic disorders. The company specializes in the research and development of MetAP-2 inhibitors and fumigillol compounds, targeting mechanisms that influence weight management and metabolic health. Additionally, Zafgen explores applications of its technology in areas such as ischemic organ damage, liver diseases, and wound healing, aiming to address significant unmet medical needs.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

48 Patents

#52 in Boston, MA

#405 in Massachusetts

#7,288 in US

#14,561 in the World

Boston, MA, United States of America

Zafgen, Inc.

Forward Citations = 283

15 inventors:

James E Vath (26 out of 27 patents)

Robert Zahler (19 out of 74 patents)

Thomas David Pallin (14 out of 30 patents)

4. Susan Mary Cramp (14 out of 15 patents)

5. Hazel Joan Dyke (13 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Zafgen, Inc.. Retrieved from https://idiyas.com/company/zafgen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…